FDA approves Boehringer Ingelheim and Eli Lilly's Glyxambi for type 2 diabetes

2 February 2015

The US Food and Drug Administration has approved Glyxambi (empagliflozin/linagliptin) tablets from German family-owned drug major Boehringer Ingelheim and Eli Lilly (NYSE: LLY) to improve glycemic control in adults with type 2 diabetes.

The drug has been approved as an adjunct to diet and exercise when empagliflozin and linagliptin are appropriate treatments. It is not recommended in type 1 diabetes patients or for the treatment of diabetic ketoacidosis, and has not been studied in patients with a history of pancreatitis, and it is unknown if using Glyxambi increases risk of pancreatitis in these patients.

It combines the dual mechanisms of action of a sodium glucose co-transporter-2 inhebitor and a dipeptidyl peptidase-4 inhibitor in a once-daily tablet taken in the morning.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK